NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer - Ophthalmology Times Europe
Links shared publicly online about this topic.
- 1,809total visits
NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer - Ophthalmology Times Europe
NicOx S.A. has signed an agreement with Pfizer Inc to reacquire the full development and commercialization rights to PF-03187207, which has completed two phase II studies in patients with primary open angle glaucoma and ocular hypertension. As part of this agreement, Pfizer has granted NicOx the right to access and use certain proprietary Xalatan (latanoprost) data.
View full resource at oteurope.com
Tags: Heart Disease, High Blood Pressure, Glaucoma, Glaucoma Medication, Xalatan, Pfizer, Ophthalmology
Most Recently Shared on August 20, 2009 at 1:40 pm By:
NicOx reacquires rights to PF-03187207 for glaucoma from Pfizer. http://ow.ly/kxUx
Advertisement
